Manufacturer
GLAXOSMITHKLINE BIOLOGICALS S.A
Contents
Inactivated HAV (HM175 strain for Havrix 1440 Adult)
Indication
Active immunisation against HAV infection in subjects at risk of exposure to HAV.
Instruction
IM Primary immunisation Adult ≥19 yr Havrix 1440 Adult 1 mL single dose in deltoid area. Childn & adolescent 1-18 yr Havrix 720 Junior 0.5 mL single dose in deltoid area (in the antero-lateral part of the thigh in young childn). Booster vaccination After primary vaccination w/ Havrix 1440 Adult or Havrix 720 Junior, a booster dose should be given between 6 mth & 5 yr, but preferably between 6 & 12 mth after primary dose.
Drug interaction
Since Havrix is an inactivated vaccine its concomitant use with other inactivated vaccines is unlikely to result in interference with the immune responses.
Havrix can be given concomitantly with any of the following vaccines: typhoid, yellow fever, cholera (injectable), tetanus, or with monovalent and combination vaccines comprised of measles, mumps, rubella and varicella.
Concomitant administration of immunoglobulines does not impact the protective effect of the vaccine.
When concomitant administration of other vaccines or of immunoglobulins is considered necessary, the products must be given with different syringes and needles and at different injection sites.
Malaysia
